A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel OTC Neuromodulation Therapy
Table 2
Baseline demographics/etiologies between total sample and study sample.
Sample population (n = 1841)
Sample with ≥2 VAS reduction at 7 days (n = 1143)
Sample with <2 VAS reduction at 7 days (n = 698)
Sample with ≥2 VAS reduction at 7 days + “definitely purchase” (n = 682)
Sample with ≥2 VAS reduction at 7-days + “not definitely purchase” (n = 461)
Study sample (n = 240)
Demographics
Age (years)
55.6
54.4
54.3
56.4
56.3
57.9
Duration of pain (years)
6.4
6.5
6.2
6.4
6.6
6.5
Women
66%
70%
61%
71%
69%
70%
Pain > than 6 months
89%
89%
88%
90%
88%
91%
Baseline VAS
8.02
8.17
7.77
8.26
8.02
8.23
7-day treatment VAS
5.03
3.38
7.72
2.97
3.97
2.82
% pain reduction
33%
59%
0%
64%
51%
66%
VAS ≥2 reduction
62%
100%
0%
100%
100%
100%
VAS ≥3 reduction
54%
87%
0%
94%
77%
97%
% “definitely purchase” intent
38%
60%
3%
100%
0%
100%
Pain etiology
Osteoarthritis
30%
31%
28%
33%
26%
25%
Rheumatoid arthritis
15%
15%
14%
15%
15%
7%
Fibromyalgia
10%
10%
9%
10%
11%
20%
Sports injury
8%
8%
7%
8%
8%
12%
Neuropathy
5%
5%
5%
5%
5%
8%
Surgery
6%
6%
5%
6%
6%
6%
Tendinitis
3%
3%
3%
3%
2%
4%
Other
23%
22%
29%
20%
27%
18%
Subjects often reported pain in multiple areas of the body, but this designation was predominantly for the back (49%), followed by knee (27%), shoulder (17%), hip (16%), neck (8%), and others (11%). The rank ordering of the locations where the PSWT medical device was applied mirrored the rank order of reported locations of pain.
